Heidelberg, September 23, 2013 – At the New Cancer Targets Conference in Heidelberg, TRON founder and scientific director Ugur Sahin will address the path towards individualized immunotherapy. Sahin is one of 30 international speakers invited by the National Center for Tumor Diseases (NCT) Heidelberg. Celebrating the 40th Heidelberg Grand Round, the 2013 Conference on New Cancer Targets gathers academics, scientists, clinicians and pharmaceutical industry representatives to reflect innovations in therapeutics development, targeted treatments and early detection and prevention strategies. The conference takes place September 23-24.
More information about the conference program can be found at their website.